LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Home・Akciju saraksts・ANI Pharmaceuticals Inc

ANI Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

82.02 0.06

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

80.88

Max

82.81

Galvenie mērījumi
By Trading Economics
Ienākumi	18M 27M
Pārdošana	16M 228M
P/E Sektora vidējais	50.838 77.671
EPS	2.04
Peļņas marža	11.684
Darbinieki	897
EBITDA	19M 61M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+35.07% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-270M 1.8B
Iepriekšējā atvēršanas cena	81.96
Iepriekšējā slēgšanas cena	82.02

Ziņu noskaņojums

By Acuity

27%

73%

87 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

70.05 / 71.85 Atbalsts un pretestība

ANI Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 10. dec. 22:02 UTC

Peļņas

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

2025. g. 10. dec. 21:46 UTC

Peļņas

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

2025. g. 10. dec. 23:52 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

2025. g. 10. dec. 23:43 UTC

Tirgus saruna

Nikkei May Rise After Fed Rate Cut -- Market Talk

2025. g. 10. dec. 23:36 UTC

Tirgus saruna

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

2025. g. 10. dec. 23:20 UTC

Peļņas

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

2025. g. 10. dec. 23:15 UTC

Peļņas

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

2025. g. 10. dec. 22:59 UTC

Tirgus saruna

Peļņas

Iegādes, apvienošanās, pārņemšana

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

2025. g. 10. dec. 22:45 UTC

Tirgus saruna

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

2025. g. 10. dec. 22:40 UTC

Peļņas

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

2025. g. 10. dec. 22:06 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

2025. g. 10. dec. 22:06 UTC

Peļņas

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

2025. g. 10. dec. 22:02 UTC

Peļņas

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

2025. g. 10. dec. 22:00 UTC

Peļņas

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

2025. g. 10. dec. 21:53 UTC

Peļņas

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

2025. g. 10. dec. 21:50 UTC

Iegādes, apvienošanās, pārņemšana

Investors Bet That a Higher Bid for Warner Is Coming -- Update

2025. g. 10. dec. 21:50 UTC

Tirgus saruna

Peļņas

Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2025. g. 10. dec. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 10. dec. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 10. dec. 21:45 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

2025. g. 10. dec. 21:33 UTC

Peļņas

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

2025. g. 10. dec. 21:32 UTC

Peļņas

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

2025. g. 10. dec. 21:28 UTC

Iegādes, apvienošanās, pārņemšana

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

2025. g. 10. dec. 21:25 UTC

Peļņas

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

2025. g. 10. dec. 21:18 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

2025. g. 10. dec. 21:16 UTC

Peļņas

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

2025. g. 10. dec. 21:15 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

2025. g. 10. dec. 21:15 UTC

Peļņas

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

2025. g. 10. dec. 21:14 UTC

Peļņas

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

2025. g. 10. dec. 21:14 UTC

Peļņas

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Salīdzinājums

Cenas izmaiņa

ANI Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

35.07% augšup

Prognoze 12 mēnešiem

Vidējais 110.8 USD 35.07%

Augstākais 121 USD

Zemākais 100 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi ANI Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam ANI Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

70.05 / 71.85Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bullish.

Noskaņojums

By Acuity

87 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par ANI Pharmaceuticals Inc

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.